Skip to main content



slipped Friday even after research firm Friedman Billings Ramsey raised its second-quarter earnings estimate for the company to 51 cents a share, 4 cents above Wall Street's consensus target. The firm also raised its sales estimates for Genentech's cancer drugs Avastin and Herceptin, and its lymphoma and rheumatoid arthritis drug Rituxan. Shares of Genentech were down 72 cents, or 0.8%, to $84.61.

Indevus Pharmaceuticals'

(IDEV) - Get Free Report

shares rose following the company's positive results from a late-stage study of its drug Sanctura XR, a treatment for people with an overactive bladder. The trial met the primary endpoint of reducing patients' frequency of urination and the secondary goals of increasing void volume and lowering the severity of urgency.

Results of the phase III study, the stage of studies conducted just prior to a drug's submission for Food and Drug Administration approval, confirmed the results of a previous trial announced last month. Indevus shares rose 9 cents, or 1.6%, to $5.65.

Shares of diagnostic-imaging services provider



soared Friday on news it plans to be acquired by

Primedex Health Systems


for about $208 million, including net debt. The deal will create the largest owner and operator of diagnostic-imaging centers in the U.S., with 132 locations, according to Primedex.

Palomar Medical Technologies


advanced $2.27, or 4.9%, to $49.11 after Standard & Poor's said it was adding the company to its Small Cap 600, replacing medical-laser developer



, which is being acquired. The switch is expected to happen after the close of trading on July 12.

Shares of German pharmaceuticals giant



were up 2.5% to $46.28 following an announcement Thursday that its diabetes-care division has acquired privately held


, a maker of diabetes-monitoring devices.

PDL BioPharma

(PDLI) - Get Free Report

tacked on 5 cents to $18.70 Friday, after falling early in the day. After the close of regular trading hours Thursday, the company said it plans to move its corporate headquarters to Redwood City, Calif., from Fremont, Calif.

Escalon Medical's


shares jumped in early trading before settling back and closing 3 cents lower at $5.05. After Thursday's market close, the company said it has named former accounting firm manager Robert O'Connor as its chief financial officer.

Nektar Therapeutics

(NKTR) - Get Free Report

settled a lawsuit brought by the University of Alabama in Huntsville regarding the company's PEGylation patent portfolio. The $25 million settlement includes a joint upfront payment by the company and its founder and former UAH employee Dr. Milton Harris. The remainder of the settlement consists of annual payments of $1 million for the next 10 years.

According to the company, as a part of the agreement, Nektar will dismiss all counterclaims related to the patent dispute. Nektar's shares fell 38 cents, or 2.2%, to $17.19.

Other health-care stocks on the move included

Vertex Pharmaceuticals

(VRTX) - Get Free Report

, 1.3% lower to $35.91, and



which fell 4% to $2.40.

Tiens Biotech Group USA


lost 4.8% to $3.80, and



dropped 7.2% to $12.16.